Optimize HCV patient management and treatment success
Delivering on clinical need requirements
These tests offer the ability to qualitatively detect hepatitis C virus or quantitatively determine amounts of HCV circulating in a patient’s blood. The test incorporates Roche’s novel dual-probe technology to address the global HCV sequence diversity with enhanced primer/probe sequence mismatch tolerance.
The diagnosis of acute and chronic HCV infection is based on the detection of HCV RNA by a sensitive molecular method (lower limit of detection greater than or equal to 15 international units IU/mL).1 The qualitative test confirms HCV antibody-positive specimens and provides evidence of an active infection. This highly sensitive test accurately detects HCV genotypes 1 through 6 with fully automated sample extraction and real-time PCR amplification and detection.
You can confidently monitor viral load results with the quantitative test at key medical decision points for optimized HCV treatment.
Effective management of HCV patients relies on accurate diagnosis. Optimize both diagnosis and treatment management for HCV infected patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV Qualitative and Quantitative Tests, v2.0.
CE-IVD: COBAS® AmpliPrep/COBAS® TaqMan® HCV v2.0 (Quantitative) and COBAS® AmpliPrep/COBAS® TaqMan® HCV v2.0 (Qualitative)
US-IVD: COBAS® AmpliPrep/COBAS® TaqMan® HCV v2.0 (Quantitative); COBAS® AmpliPrep/COBAS® TaqMan® HCV v2.0 (Qualitative) not available in the United States